254 related articles for article (PubMed ID: 22050016)
61. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
62. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
63. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
Mikes RE; Jordan F; Hutarew G; Studnicka M
Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
[TBL] [Abstract][Full Text] [Related]
64. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
de Castro-Carpeño J; Perona R; Belda-Iniesta C
Clin Transl Oncol; 2011 Nov; 13(11):774-9. PubMed ID: 22082640
[TBL] [Abstract][Full Text] [Related]
65. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
Thunnissen E; Bubendorf L; Dietel M; Elmberger G; Kerr K; Lopez-Rios F; Moch H; Olszewski W; Pauwels P; Penault-Llorca F; Rossi G
Virchows Arch; 2012 Sep; 461(3):245-57. PubMed ID: 22825000
[TBL] [Abstract][Full Text] [Related]
66. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.
Solomon B; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2009 Dec; 4(12):1450-4. PubMed ID: 20009909
[TBL] [Abstract][Full Text] [Related]
67. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
68. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
Yi ES; Chung JH; Kulig K; Kerr KM
Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
[TBL] [Abstract][Full Text] [Related]
69. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
70. [A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors
and Chemotherapy].
Wang J; Xu X; Sun Y; Li H
Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):372-376. PubMed ID: 34034462
[TBL] [Abstract][Full Text] [Related]
71. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
[TBL] [Abstract][Full Text] [Related]
72. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
[TBL] [Abstract][Full Text] [Related]
73. Crizotinib.
Heigener DF; Reck M
Recent Results Cancer Res; 2014; 201():197-205. PubMed ID: 24756793
[TBL] [Abstract][Full Text] [Related]
74. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract][Full Text] [Related]
75. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
[TBL] [Abstract][Full Text] [Related]
76. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
77. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.
Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564
[No Abstract] [Full Text] [Related]
78. The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.
Pillai RN; Ramalingam SS
Curr Oncol Rep; 2012 Apr; 14(2):105-10. PubMed ID: 22311682
[TBL] [Abstract][Full Text] [Related]
79. [EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy].
Vašíková A
Klin Onkol; 2012; 25(6):434-9. PubMed ID: 23301645
[TBL] [Abstract][Full Text] [Related]
80. [Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer].
Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2014 Dec; 17(12):850-4. PubMed ID: 25539610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
